EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS

K. Gordon,J. F. Merola,P. Foley,O. Choi,D. Chan,M. Miller,Y. You,Y. K. Shen,Y. W. Yang,A. Blauvelt

Journal of the American Academy of Dermatology（2022）

引用 0|浏览3

暂无评分

摘要

Introduction: VOYAGE-1&2 phase 3 studies evaluated efficacy and safety of guselkumab (GUS) in patients with moderate-to-severe plaque psoriasis. Five-year efficacy was examined by baseline disease characteristics and treatment history.

查看译文

关键词

severe plaque psoriasis,guselkumab,disease severity,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要